Skip to main content
Middle East Pharmaceutical Industries Co. logo

Middle East Pharmaceutical Industries Co. — Investor Relations & Filings

Ticker · 4016 ISIN · SA160G51UO10 Saudi Exchange Manufacturing
Open in API
Filings indexed 42 across all filing types
Latest filing 2026-05-12 Declaration of Voting R…
Country SA Saudi Arabia
Listing Saudi Exchange 4016

About Middle East Pharmaceutical Industries Co.

http://www.avalonpharmaceutical.com

Middle East Pharmaceutical Industries Co., operating under the brand name Avalon Pharma, specializes in the development, manufacturing, and marketing of a diverse range of health products. The company maintains a robust portfolio focusing on therapeutic areas such as dermatology, respiratory care, oral health, and hygiene solutions. Its operations are characterized by a commitment to high-quality manufacturing standards and extensive research and development initiatives. The organization provides a variety of prescription medications and over-the-counter treatments, catering to healthcare professionals and consumers alike. It emphasizes innovation and the continuous expansion of its product lines to address evolving medical needs and maintain a competitive presence.

Recent filings

Filing Released Lang Actions
Middle East Pharmaceutical Industries Co. Announces the Results of the Extraordinary General Assembly’s Meeting Included the Approval of the Company’s Capital Increase. (First Meeting)
Declaration of Voting Results & Voting Rights Announcements Classification · 96% confidence The document is an issuer announcement that provides the formal results of an Extraordinary General Assembly meeting, including voting outcomes on agenda items (specifically, the approval of a capital increase). It fits the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-05-12 English
Middle East Pharmaceutical Industries Co. announces its Interim Financial results for the Period Ending on 2026-03-31 (Three Months)
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Middle East Pharmaceutical Industries Co. announces its Interim Financial results for the Period Ending on 2026-03-31 (Three Months)', indicating it is an interim financial report. It contains detailed financial data such as sales/revenue, gross profit, operational profit, net profit, shareholders equity, and profit per share for the quarter ending March 31, 2026. The presence of comparative figures for the previous quarter and the same quarter last year, along with explanations for changes in financial results, confirms it is a comprehensive interim report. The document length is over 6000 characters and includes substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-05-06 English
Correction announcement from Middle East Pharmaceutical Industries Co. in regards to the Details of the Electronic Voting Feature on the Agenda Items of the Extraordinary General Assembly.
Regulatory Filings Classification · 87% confidence The document is a short correction notice to a previous issuer announcement concerning electronic voting details for an Extraordinary General Assembly. It does not present full meeting materials, voting results, or financial data, nor is it the actual AGM presentation or proxy statement. It is a miscellaneous regulatory announcement correcting earlier disclosure, fitting the fallback Regulatory Filings category.
2026-04-21 English
Middle East Pharmaceutical Industries Co. calls its shareholders to attend the Extraordinary General Assembly meeting which include the Increase of the company’s capital ( First Meeting )
Proxy Solicitation & Information Statement Classification · 90% confidence The document is an issuer announcement calling shareholders to attend an Extraordinary General Assembly meeting, outlining the meeting date, agenda (including capital increase), proxy form, voting procedures, and participation details. This constitutes solicitation and information materials for a shareholder vote rather than reporting financial results or declaring outcomes. Therefore it best fits “Proxy Solicitation & Information Statement” (Code: PSI).
2026-04-20 English
Middle East Pharmaceutical Industries Co. Announces the formation of its Audit Committee.
Board/Management Information Classification · 85% confidence The document is a regulatory announcement on the Saudi Exchange detailing the formation and membership appointments of the company’s Audit Committee for the new board term, including names, start dates, and resumes. This is an announcement of changes in the company’s board committee structure, fitting the Board/Management Information category (MANG).
2026-04-16 English
Middle East Pharmaceutical Industries Co. Announces the appointment of the Chairman and Vice Chairman of the Board, the formation of the Board’s Committees, and the appointment of the Board’s Secretar
Board/Management Information Classification · 95% confidence The document is an issuer announcement disclosing the appointment of the Chairman and Vice Chairman of the board, the formation of board committees, and the appointment of the board secretary and company representatives. This clearly pertains to changes in the company’s board of directors and senior management. Therefore, it falls under Board/Management Information (MANG).
2026-04-16 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.